From Labor Markets to the AI Fringe: A Cross-Section of the 2026 EconomyGlobal Report·1 day ago, 04:13 AMATYR-4.98%AMPGR0.00%
aTyr Pharma submits FDA protocol for planned Phase 3 efzofitimod sarcoidosis studyPUBT·Jul 15 at 07:02 AMATYR-4.98%
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026Unusual Whales·Jul 15 at 07:02 AMATYR-4.98%
ATYR: Efzofitimod advances toward approval with a new phase III trial targeting restrictive sarcoidosisQuartr·Jun 25 at 03:55 PMATYR-4.98%
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga_article·May 28 at 04:05 PMARTV-0.99%ATYR-4.98%
RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)Tip Ranks·May 18 at 08:46 PMATYR-4.98%SBIO-0.88%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·May 14 at 07:05 AMQUCY-2.70%STAA-3.35%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·May 12 at 12:06 PMSMTI+0.24%ATYR-4.98%
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis TrialMarket Beat·May 11 at 07:09 PMATYR-4.98%BBH-0.23%
